New directions in drug discovery and development
Roche Genentech R&D is driven by two autonomous R&D centers gRED, Genentech & pRED, Roche Pharma Research & Exploratory Development. Andreas Wallnoefer is the Global Head of pRED Development and is a member of the pRED Leadership Team. He is also a cor…more ›
Nigel Dallow is a Director of Clinical Statistics at GlaxoSmithKline supporting the respiratory area. Nigel has vast experience in working in drug development especially in the early phase area having worked at GSK for 17 years. Though his experiences, Nigel has a stron…more ›
Richard leads a lab focused on the application of mass-spectrometry to achieve high confidence read outs of biomarkers across the R&D organization at Actelion. The work covers both protein and metabolite measurements. The Lab is embedded in the translational-science…more ›
Covering the strategic use of biomarkers in drug discovery and development
Biomarker professionals will gather together to answer the all important question- how can we get biomarkers to add value? How do you develop new medicines which demonstrate real value through predictable outcomes in targeted patient groups?
The event is a two day strategic conference tackling these questions and providing participants with a thorough review of the use of biomarkers, their effectiveness and their potential to transform R & D.
New for 2012 –
Pharmaceutical and Biotech registration reduced by 50%
Scientific Poster Display – an opportunity for researchers and practitioners to present their new and innovative work-in-progress
Sponsors
Come to Biomarkers World Europe and learn:
- How to support target identification and eliminate dead-end candidates
- How to understand the range of biomarker candidates
- How to create sophisticated animal models of human disease to develop biomarkers for proof-of pharmacology
- How to facilitate clinical trial stratification and employ early surrogate end points of efficacy
- How to define the correlation between biomarker and disease/therapeutic intervention
- How to develop fit-for-purpose biomarker assays
- How to show the clinical utility of biomarkers to improve diagnosis and make informed decision making
Who's attending:
- Head of Drug Discovery
- Head of Pharmacology
- Head of Biomarker Development
- Head of Clinical Biomarkers
- Head of Assay Development
- Head of Translational Medicine
- Head of Diagnostics
- Head of Clinical Imagings
- Head of Pharmacogenomics
- Head of Metabolism
- Head of Bioanalysis
- Head of Personalised Medicine
World class CRO or technology providers attend:
- To showcase their services to their target audience
- To meet senior biomarker professionals
- To position their brand as a leader in the pharma & biotech market
- To generate leads and new business
Submit a poster:
In 2012, Health Network Communications is introducing a poster session and opportunities to submit a poster are now available.
